Home > Medical Research Archives > Issue 149 > Molecular Features and Targeted Therapy in KRAS wild-type Pancreatic Cancer
Published in the Medical Research Archives
Apr 2023 Issue
Molecular Features and Targeted Therapy in KRAS wild-type Pancreatic Cancer
Published on Apr 25, 2023
DOI
Abstract
KRAS mutation is the major oncogenic event in approximately 90% of pancreatic ductal adenocarcinomas. The subset of patients with KRAS wild-type pancreatic ductal adenocarcinomas represent a distinct subgroup with a higher frequency of actionable genomic alterations. In this review article, we aim at exploring the more frequent molecular alterations found among KRAS wild-type pancreatic ductal adenocarcinomas, their prognostic implications, as well as the potential targetable therapeutic options beyond cytotoxic chemotherapy for this unique subset of patients.
Author info
Renata Peixoto, Maria Mathias-machado, Leandro Oliveira, Victor Fonseca De Jesus
Author Area
Have an article to submit?
Submission Guidelines
Submit a manuscript
Become a member